Roche of Switzerland lands at #5 ($4.09 Eur) in the top 15 R&D spenders and #6 in overall sales. The company spent 2007 restructuring its research facilities and divided R&D into 5 categories: oncology, virology, inflammation, metabolism and the central nervous system. Its cancer drug, Avastin, has 9 additional indications of use in Phase III trials and three more are pending. The company has 40 drugs in Phase III trials, 32 in Phase II and 34 in Phase I.
Drugs Pending Approval:
Xeloda - Oral fluoropyrimidine metastatic colorectal cancer (1st line) combo, oral fluoropyrimidine metastatic colorectal cancer (2nd line) combo
Avastin - Renal cell carcinoma, metastatic colorectal cancer (1st line) combo oxaliplatin, Metastic breast cancer (1st line) combo taxol
Nicorandil (Sigmart) - Acute heart failure
Phase III:
Rituximab MabThera / Rituxan - Rheumatoid arthritis
Tocilizumab (Actemra) - Rheumatoid arthritis, Systemic Onset of Juvenile Idiopathic arthritis
Ocrelizumab - Rheumatoid arthritis
Rituximab (MabThera/ Rituxan) - Chronic lymphocytic leukemia, chronic lymphocytic leukemia (relapsed)
Rituximab (MabThera / Rituxan) - Maintenance indolent NHL 1st line
Erlotinib (Tarceva) - Non-small cell lung cancer (1st line maintenance) combo with chemotherapy, Adjuvant non-small cell lung cancer, Inhibitor non-small cell lung cancer (2nd line) combo Avastin
Capecitabine (Xeloda) - Oral fluoropyrimidine adjuvant CC combo Avastinm, oral fluoropyrimidine adjuvant CC combo Avastin, oral fluoropyrimidine adjuvant breast cancer
Bevacizumab (Avastin) - Metastatic gastric cancer, adjuvant CC, mBC (1st line) combo non-taxanes, mBC (1st line) combo taxotere, non-small cell lung cancer 1st line maintenance (combo Tarceva), ovarian cancer, pancreatic cancer, prostate cancer, adj non-small cell lung cancer, aggressive NHL, mBC (1st line) combo Herceptin
Trastuzumab (Herceptin) - Metastatic gastric cancer
Valganciclovir (Valcyte) - CMV replication
Rituximab (MabThera/ Rituxan) - Antineutrophil Cytoplasmic Antibodies-associated vasculitis, Systemic Lupus Erythematodes
Rituximab (MabThera/ Rituxan) - AI PMS, Lupus nephritis
Bevacizumab (Avastin) - Metastatic breast cancer (2nd line), adjuvant rectal cancer, GIST recurrent
Tenecteplase (TNKase) - Catheter clearance
Nicaraven (Antevas) - Subarachnoid hemorrhage
EPOCH - Chemotherapy induced anemia
Lucentis - Retinal vein occlusion, diabetic macular edema
Xolair - Pediatric asthma
[Source: FierceBiotech]
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 11, 2007 1:14 PM | Permalink to Trackback